“…Fifteen repetitive separations of 10 μL each of a 12.5 mg/mL solution allowed cumulative trapping of 18 peaks (Figure S1, Supporting Information). Using the peak and compound numbering scheme (in italics and bold, respectively) as for the subsequent HPLC-PDA-HRMS-SPE-cryoNMR analysis of preparative-scale fractions (Figure 1), the compounds eluted with eight of the trapped peaks were identified as (Z)-6-(4-hydroxy-3-methylbut-2-en-1-yl)coumarin 7-O-β-D-glucopyranoside (5), 19 7-(2,3-dihydroxy-3-methylbutyloxy)coumarin ( 9), 4 8-(2,3-dihydroxy-3-methylbutyloxy)-7-methoxycoumarin (12), 20 8-(2-hydroxy-3-methylbut-3-en-1-yloxy)-7-methoxycoumarin ( 16), 20 6-(2-hydroxy-3-methylbut-3-en-1-yl)-7-methoxycoumarin (17), 21 6-(2,3-dihydroxy-3-methylbutyl)-7methoxycoumarin (18), 5 (E)-3,7-dimethylocta-2,6-dien-1-yl 2-((3-methylbut-2-en-1-yl)amino)benzoate (25), 22 and (2E,4E)-N-isobutyldeca-2,4-dienamide (26) 23 with the remaining eight peaks in the pilot project could not be established unambiguously. However, as the obtained NMR and MS data suggested the presence of additional glycosylated and chlorinated coumarins, it was decided to perform preparative-scale HPLC separation using a C 18 column, followed by HPLC-PDA-HRMS-SPE-cryoNMR analysis of all fractions using an analytical-scale pentafluorophenyl (PFP) column.…”